Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer - No Study Results Posted

Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer (COMET-2)

This study is currently recruiting participants.

Study NCT01522443 Information provided by Exelixis

First Received: January 13, 2012 Last Updated: May 24, 2012 History of Changes

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Study Status:	This study is currently recruiting participants.
Estimated Study Completion Date:	No date given
Estimated Primary Completion Date:	June 2013 (Final data collection date for primary outcome measure)